Denali Therapeutics Inc [DNLI] stock is trading at $29.55, up 6.87%. An important factor to consider is whether the stock is rising or falling in short-term value. The DNLI shares have gain 10.06% over the last week, with a monthly amount glided 10.55%, and seem to be holding up well over a long-time horizon.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
From an analyst’s perspective:
Previously, Cantor Fitzgerald downgraded its rating to Neutral on October 07, 2024. On December 13, 2023, Citigroup initiated with a Buy rating and assigned a price target of $32 on the stock. B. Riley Securities started tracking with a Buy rating for this stock on September 06, 2023, and assigned it a price target of $38. In a note dated January 30, 2023, SVB Securities initiated an Outperform rating and provided a target price of $50 on this stock.
Denali Therapeutics Inc [DNLI] stock has fluctuated between $14.56 and $32.13 over the past year. Currently, Wall Street analysts expect the stock to reach $40 within the next 12 months. Denali Therapeutics Inc [NASDAQ: DNLI] shares were valued at $29.55 at the most recent close of the market. An investor can expect a potential return of 35.36% based on the average DNLI price forecast.
Analyzing the DNLI fundamentals
Denali Therapeutics Inc [NASDAQ:DNLI] reported sales of 1.27M for the trailing twelve months, which represents a drop of -100.00%. Gross Profit Margin for this corporation currently stands at 1.03% with Operating Profit Margin at 1.63%, Pretax Profit Margin comes in at 1.38%, and Net Profit Margin reading is 1.38%. To continue investigating profitability, this company’s Return on Assets is posted at -0.28, Equity is -0.34 and Total Capital is -0.35. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 0.04.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 28.65 points at the first support level, and at 27.75 for the second support level. However, for the 1st resistance point, the stock is sitting at 30.02, and for the 2nd resistance point, it is at 30.50.
Ratios To Look Out For
For context, Denali Therapeutics Inc’s Current Ratio is 12.46. On the other hand, the Quick Ratio is 12.46, and the Cash Ratio is 1.0. Considering the valuation of this stock, the price to sales ratio is 3331.13, the price to book ratio is 3.05.
Transactions by insiders
Recent insider trading involved SATO VICKI L, Director, that happened on Nov 01 ’24 when 3080.0 shares were sold. President and CEO, Watts Ryan J. completed a deal on Oct 18 ’24 to sell 40000.0 shares. Meanwhile, Director RYAN WATTS bought 40000.0 shares on Oct 18 ’24.
